Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 8/20 | 0.68 |
| ▸ | CFTR | P13569 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.45 |
| ▸ | CYP3A5 | P20815 | 5/20 | 0.45 |
| ▸ | VDR | P11473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4067517 | 0.86 | CFTR (0.65) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4198760 | 0.86 | CFTR (0.64) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6502308 | 0.82 | CYP19A1 (0.50) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10674497 | 0.81 | CYP19A1 (1.00) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2124049 | 0.80 | IDO1 (0.56) | CYP19A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11374142 | 0.79 | CYP19A1 (0.70) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6501455 | 0.78 | CYP19A1 (0.68) | CYP19A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2908868 | 0.78 | SMN1; SMN2 (0.72) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2914172 | 0.78 | CYP19A1 (0.68) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3832267 | 0.78 | CYP19A1 (0.68) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043313-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043313-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | TFPI, TFPI2, PLAT | CYP19A1 1130/4885CFTR 3800/4885SLC6A2 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.